Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-24T11:30:32.203Z Has data issue: false hasContentIssue false
  • English
  • Français

The use of selective serotonin reuptake inhibitors in geriatric depression: a review of the literature

Published online by Cambridge University Press:  17 November 2008

Richard Marc Patel  and
George T Grossberg
Richard Marc Patel*
Affiliation:
Stanford University Hospitals, Psychiatry, Stanford, California
George T Grossberg
Affiliation:
Saint Louis University Medical Center, Psychiatry, St Louis, Missouri, USA
*
Richard Marc Patel, 45 Montcalm Street, San Francisco, California 94110, USA.
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Psychiatry of old age
Information
Reviews in Clinical Gerontology , Volume 5 , Issue 4 , November 1995 , pp. 442 - 455
Copyright
Copyright © Cambridge University Press 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Schnieder, JS, Reynolds, CF, Lebowitz, BD, Friedhoff, AJ. Diagnosis and treatment of depression in later life. Washington, DC: American Psychiatric Press, 1994.Google Scholar
2Lapin, IP, Oxenkrug, GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969; i: 132–36.CrossRefGoogle Scholar
3Meltzer, HY, Lowy, MT. The serotonin hypothesis of depression. In: Meltzer, HY ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 513–26.Google Scholar
4Koenig, HG, Blazer, DG. Epidemiology of geriatric affective disorders. Clin Geriatric Med 1992; 8: 235–51.CrossRefGoogle ScholarPubMed
5Snowdon, J. The prevalence of depression in old age. Int J Geriatric Psychiatry 1990; 5: 141–44.CrossRefGoogle Scholar
6Rovner, BW, German, PS, Brant, LJ et al. Depression and mortality in nursing homes. JAMA 1991; 265: 993–96.CrossRefGoogle ScholarPubMed
7Blazer, D. Depression in the elderly. N Engl J Med 1989; 320: 164–66.CrossRefGoogle ScholarPubMed
8Sulser, F, Janowsky, AJ, Okada, F, Manier, DH, Mobley, PL. Regulation of recognition and action function of norepinephrine (NE) receptor-coupled adenylate cyclase system in brain: implications for the therapy of depression. Neuropharmacology 1983; 22: 425–31.CrossRefGoogle ScholarPubMed
9Guthrie, SK. Sertraline: a new specific serotonin reuptake blocker. DICP, Ann Pharmacother 1991; 25: 952–61.CrossRefGoogle ScholarPubMed
10Stark, P, Fulle, RW, Wong, DT. The pharmacologic profile of fluoxetine. J Clin Psychiatry 1985; 46: 7–13.Google ScholarPubMed
11Pujol, JF, Keane, P, McRae, A et al. Biochemical evidence for serotonergic control of the locus ceruleus. In: Garatinni, S, Pujol, JF, Samanin, R eds. Interactions between putative neurotransmitters in the brain. New York: Raven Press, 1978: 401–10.Google Scholar
12Wang, RY, Aghajanian, GK. Collateral inhibition of serotonergic neurons in the dorsal raphe nucleus: pharmacological evidence. Neuropharmacology 1987; 17: 819–25.CrossRefGoogle Scholar
13Feuerstein, TJ, Hertting, G. Serotonin (5-HT) enhances hippocampal noradrenaline (NA) release: evidence for facilitatory 5-HT receptors within the CNS. Naunyn Schmiedebergs Arch Pharmacol 1986; 333: 191–97.CrossRefGoogle ScholarPubMed
14Doogan, DP, Callard, V. Sertraline: a new antidepressant. J Clin Psychiatry 1988; 49 (suppl 8): 46–51.Google ScholarPubMed
15Shopsin, B, Friedman, E, Gershon, S. Pharachlorphenylalanine reversal of tranylcypramine effects in depressed patients. Arch Gen Psychiatry 1976; 33; 811–19.CrossRefGoogle Scholar
16Grimsley, SR, Jann, MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharmacy 1992; 11: 930–57.Google ScholarPubMed
17Lemberger, L, Bergstrom, RF, Wolen, RL et al. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985; 46: 14–19.Google ScholarPubMed
18Bergstrom, RF, Lemberger, L, Farid, NA, Wolen, RL. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry 1988; 153 (suppl 3): 47–50.CrossRefGoogle Scholar
19Mellerup, ET, Plenge, P. High affinity binding of 3H-paroxetine and 3H-imipramine to rat neuronal membranes. Psychopharmacology 1986; 89: 436–39.CrossRefGoogle ScholarPubMed
20Preskorn, SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993; 2(94): 2S–12S.Google Scholar
21Bayer, AJ, Roberts, NA, Allen, EA et al. The pharmacokinetics of paroxetine in the elderly. Acta Psychiatr Scand 1989; 80 (suppl 350): 85–86.CrossRefGoogle Scholar
22Lundmark, J, Thomsen, IS, Fjord-Larsen, T et al. Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand 1989; 80 (suppl 350): 76–80.CrossRefGoogle Scholar
23Haddock, RE, Johnson, AM, Langley, PF et al. Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatr Scand 1989; 80 (suppl 350): 24–26.CrossRefGoogle Scholar
24Kaye, CM, Haddock, RE, Langley, PF et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989; 80 (suppl 350): 60–75.CrossRefGoogle Scholar
25Tasker, TCG, Kaye, CM, Zussman, BD, Link, CGG. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand 1989; 80 (suppl 350): 152–55.CrossRefGoogle Scholar
26Koe, BK. Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. J Clin Psychiatry 1990; 51 (suppl B): 13–17.Google ScholarPubMed
27Johnson, AM. An overview of the animal pharmacology of paroxetine. Acta Psychiatr Scand 1989; 80 (suppl 350): 14–20.CrossRefGoogle Scholar
28Dunbar, GC. An interim overview of the safety and tolerability of paroxetine. Acta Psychiatr Scand 1989; 80 (suppl 350): 135–37.CrossRefGoogle Scholar
29Schmidt, MJ, Fuller, RW, Wong, DT. Fluoxetine, a highly selective serotonin reuptake inhibitor: a review of preclinical studies. Br J Psychiatry 1988; 153 (suppl 3): 40–46.CrossRefGoogle Scholar
30Fredericson, O-K. Kinetics of citalopram in elderly patients. Psychopharmacology 1985; 86: 253–57.CrossRefGoogle Scholar
31Schatzberg, AF. Dosing strategies for antidepressant agents. J Clin Psychiatry 1991; 52 (5 suppl): 14–20.Google ScholarPubMed
32Altamura, AC, Montgomery, SA, Wernicke, JF. The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatry 1988; 153 (suppl 3): 109–12.CrossRefGoogle Scholar
33Salzman, C. Monoamine oxidase inhibitors and atypical antidepressants. Clin Geriatric Med 1992; 8: 335–48.CrossRefGoogle ScholarPubMed
34Guthrie, SK. Sertraline: a new specific serotonin reuptake blocker. DICP, Ann Pharmacother 1991; 25: 952–61.CrossRefGoogle ScholarPubMed
35Berman, I, Sapers, BL, Salzman, C. Sertraline: a new sertonergic antidepressant. Hosp Commun Psychiatry 1992; 43: 671–72.Google Scholar
36Jenner, PN. Paroxetine: an overview of dosage, tolerability, and safety. Int Clin Psychopharmacol 1992; 6 (suppl 4): 69–80.CrossRefGoogle ScholarPubMed
37Feighner, JP, Cohn, JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry 1985; 46(3): 20–25.Google ScholarPubMed
38Feighner, JP, Boyer, WF, Meredith, CH, Hendrickson, G. An overview of fluoxetine in geriatric depression. Br J Psychiatry 1988; 153 (suppl 3): 105–108.CrossRefGoogle Scholar
39Altamura, AC, de Novellis, F, Guercetti, G et al. Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. Int J Clin Pharmacol Res 1989; IX: 391–96.Google Scholar
40Conn, CK, Shrivastava, R, Mendels, J et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990; 51 (12 suppl): 28–33.Google Scholar
41Dunner, DL, Cohn, JB, Walshe, T III et al. Two combined, multi-centre double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992; 53 (suppl 2): 57–60.Google Scholar
42Guillibert, E, Pelicier, Y, Archambault, JC et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand 1989; 80 (suppl 350): 132–34.CrossRefGoogle Scholar
43Wakelin, JS. Fluvoxamine in the treatment of the older depressed patient: double-blind, placebo-controlled data. Int Clin Psychopharmacol 1986; 1: 221–30.CrossRefGoogle ScholarPubMed
44Phanjoo, AL, Wonnacott, S, Hodgson, A. Double-blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people. Acta Psychiatr Scand 1991; 83: 476–79.CrossRefGoogle ScholarPubMed
45Schone, W, Ludwig, M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993; 13 (6 suppl 2): 34S–39S.Google ScholarPubMed
46Wagner, W, Plekkenpol, B, Gray, TE. Review of fluvoxamine safety database. Drugs 1992; 43 (suppl 2): 48–54.CrossRefGoogle ScholarPubMed
47Benfield, P, Ward, A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 313–34.CrossRefGoogle ScholarPubMed
48Howard, R, Bandyopadhyay, D. Selective serotonin reuptake inhibitors for the elderly. Int J Geriatric Psychiatry 1992; 8: 627–29.CrossRefGoogle Scholar
49Reimherr, FW, Chouinard, G, Cohn, CK et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51 (12 suppl B): 18–27.Google ScholarPubMed
50Heym, J, Koe, BK. Pharmacology of sertraline: a review. J Clin Psychiatry 1988; 49 (8 suppl): 40–45.Google ScholarPubMed
51Wurtman, JJ, Wurtman, RJ. Fenfluramine and fluoxetine spare protein consumption while suppressing caloric intake by rats. Science 1977; 198: 1178–80.CrossRefGoogle ScholarPubMed
52Crews, J, Potts, N, Schreiber, J, Lipper, J. Hyponatremia in a patient treated with sertraline [Letter]. Am J Psychiatry 1993; 150: 1517.Google Scholar
53Belanoff, J, Sheikh, JI. Hyponatremia as a side effect of selective serotonin reuptake inhibitors. Am J Geriatric Psychiatry 1994 (in press).Google Scholar
54Feighner, JP, Boyer, WF. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatr Scand 1989; 80 (suppl 350): 125–29.CrossRefGoogle Scholar
55Wurtman, JJ. Discussion: conference on sertraline. J Clin Psychiatry 1988; 49 (8 suppl): 72–73.Google Scholar
56Cooper, GL. The safety of fluoxetine – an update. Br J Psychiatry 1988; 153 (suppl 3): 77–86.CrossRefGoogle Scholar
57Byerley, WF, Reimherr, FW, Wood, DR. Fluoxetine, a selective serotonin uptake inhibitor for the treatment of outpatients with major depression. J Clin Psychopharmacol 1988; 8: 112–15.CrossRefGoogle ScholarPubMed
58Cole, JO. New directions in antidepressant therapy: a review of sertraline, a unique serotonin reuptake inhibitor. J Clin Psychiatry 1992; 53: 333–40.Google ScholarPubMed
59Cole, JO, Bodkin, JA. Antidepressant drug side effects. J Clin Psychiatry 1990; 51 (1 suppl): 21–26.Google ScholarPubMed
60Schweizer, E, Rickeis, K. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1990; 51 (12 suppl B): 9–12.Google Scholar
61Fisch, C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985; 46: 42–44.Google ScholarPubMed
62Buff, DD, Brenner, R, Kirtane, SS, Gilboa, R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991; 52: 174–76.Google Scholar
63Ellison, JM, Milogsky, JE, Ely, E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1990; 51: 385–86.Google ScholarPubMed
64Halper, JP, Mann, JJ. Cardiovascular effects of antidepressant medications. Br J Psychiatry 1988; 152 (suppl 3): 87–98.CrossRefGoogle Scholar
65Wernicke, JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985; 46: 59–67.Google ScholarPubMed
66Mattila, MJ, Saarialho-Kere, U, Manila, M. Acute effects of sertraline, amitriptyline, and placebo on the psychomotor performance of healthy subjects over 50 years of age. J Clin Psychiatry 1988; 49 (8 suppl): 52–58.Google ScholarPubMed
67Musher, JS. Anorgasmia with the use of fluoxetine [Letter]. Am J Psychiatry 1990; 147: 948.Google ScholarPubMed
68Smith, D, Levitte, S. Association of fluoxetine and return of sexual potency in three elderly men. J Clin Psychiatry 1993; 54: 317–19.Google ScholarPubMed
69Hwang, AS, Magraw, RM. Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine [Letter]. Am J Psychiatry 1989; 146: 399.Google ScholarPubMed
70Cohen, JB, Mahelsky, M, Adler, L [Letter]. More cases of SIADH with fluoxetine. Am J Psychiatry 1990; 147: 948–49.Google ScholarPubMed
71Gommare, JH, Edwards, RA. Fluoxetine and hyponatremia [Letter]. N Z Med J 1990; 105: 106.Google Scholar
72Vishvanuth, B, Navalgund, AA, Cosano, W, Nagaland, HA. Fluoxetine as a cause of SIADH [Letter]. Am J Psychiatry 1991; 148: 542–43.Google Scholar
73Goddard, C, Paton, C. Hyponatremia associated with paroxetine [Letter]. BMJ 1993; 306: 143.Google Scholar
74Chun, TP, Vong, SH. Hyponatremia associated with paroxetine [Letter]. BMJ 1993; 306: 143.Google Scholar
75Lipinski, JF Jr, Mallya, G, Zimmerman, P et al. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339–42.Google ScholarPubMed
76Rothschild, AJ, Locke, CA. Re-exposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991; 52: 491–93.Google Scholar
77Black, B, Uhde, TW [letter]. Acute dystonia and fluoxetine. J Clin Psychiatry 1992; 53: 327.Google ScholarPubMed
78Bouchard, RH, Pourcher, E, Vincent, P. Fluoxetine and extra-pyramidal side effects [Letter]. Am J Psychiatry 1989; 146: 1352–53.Google Scholar
79Baldwin, D, Fineberg, N, Montgomery, S. Fluoxetine, fluvoxamine, and extra-pyramidal disorders. Int Clin Psychopharmacol 1991; 6: 51–58.CrossRefGoogle Scholar
80Hebenstreit, GF, Fellerer, K, Zochling, R, Zentz, A, Dunbar, GC. A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta Psychiatr Scand 1989; 80 (suppl 350): 81–84.CrossRefGoogle Scholar
81Chouinard, G, Jones, B. No crossover of hypersensitivity between zimelidine and fluoxetine. Can Med Assoc J 1984; 131: 1190.Google ScholarPubMed
82Figiel, GS, Krishnan, KRR, Breitner, JC, Nemeroff, CB. Radiologic correlates of antidepressant-induced delirium: the possible significance of basal-ganglia lesions. J Neuropsychiatry 1989; 1: 188–90.Google ScholarPubMed
83Hindmarsh, I, Shillingford, J, Shillingford, C. The effects of sertraline on psychomotor performance in elderly volunteers. J Clin Psychiatry 1990; 51 (12 suppl B): 34–36.Google Scholar
84Hindmarch, I, Harrison, C. The effects of paroxetine and other antidepressants in combination with alcohol on psychomotor activity related to car driving. Acta Psychiatr Scand 1989; 80 (suppl 350): 45–49.CrossRefGoogle Scholar
85Sternbach, H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988; ii: 850–51.CrossRefGoogle Scholar
86Dursun, S, Mathew, VM, Reveley, MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine [Letter]. Lancet 1993; 342: 442–43.CrossRefGoogle ScholarPubMed
87Pearson, H. Interaction of fluoxetine with carbamazepine [letter]. J Clin Psychiatry 1990; 51: 126.Google ScholarPubMed
88Cowen, P, Thompson, C, Roberts, A et al. Selective serotonin reuptake inhibitors. BMJ 1994; 309: 1082–85.CrossRefGoogle ScholarPubMed